| Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib A Noeparast, E Teugels, P Giron, G Verschelden, S De Brakeleer, ... Oncotarget 8 (36), 60094, 2017 | 101 | 2017 |
| Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer A Noeparast, P Giron, S De Brakeleer, C Eggermont, U De Ridder, ... Oncotarget 9 (22), 16110, 2018 | 33 | 2018 |
| Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2 Z Ren, JL Aerts, H Vandenplas, JA Wang, O Gorbenko, JP Chen, P Giron, ... Cell Death & Disease 7 (12), e2560-e2560, 2016 | 32 | 2016 |
| CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition A Noeparast, P Giron, A Noor, R Bahadur Shahi, S De Brakeleer, ... Oncogene 38 (31), 5933-5941, 2019 | 27 | 2019 |
| Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer I Umelo, A Noeparast, G Chen, M Renard, C Geers, J Vansteenkiste, ... Oncotarget 7 (3), 3068, 2016 | 27 | 2016 |
| USP13 controls the stability of Aurora B impacting progression through the cell cycle M Esposito, HB Akman, P Giron, MA Ceregido, R Schepers, ... Oncogene 39 (37), 6009-6023, 2020 | 20 | 2020 |
| Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages Y De Vlaeminck, Q Lecocq, P Giron, C Heirman, X Geeraerts, E Bolli, ... Journal of controlled release 299, 107-120, 2019 | 19 | 2019 |
| Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer P Giron, C Eggermont, A Noeparast, H Vandenplas, E Teugels, R Forsyth, ... International Journal of Cancer 148 (10), 2579-2593, 2021 | 17 | 2021 |
| In silico design and validation of ovmane1, a chimeric antigen for human onchocerciasis diagnosis CM Shintouo, RA Shey, DN Nebangwa, K K. Esoh, NF Nongley, ... Pathogens 9 (6), 495, 2020 | 10 | 2020 |
| Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector A Noor, G Walser, M Wesseling, P Giron, AM Laffra, F Haddouchi, ... BMC research notes 11, 1-7, 2018 | 10 | 2018 |
| The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations L Decoster, P Giron, S Mignon, J De Grève Translational Lung Cancer Research 7 (Suppl 2), S134, 2018 | 7 | 2018 |
| Structure–Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors M Elsocht, P Giron, L Maes, W Versées, GJ Gutierrez, J De Grève, S Ballet International Journal of Molecular Sciences 22 (2), 635, 2021 | 6 | 2021 |
| Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer A Noor, IA Umelo, P Kronenberger, P Giron, E De Vlieghere, O De Wever, ... Oncotarget 9 (47), 28731, 2018 | 6 | 2018 |
| The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer C Eggermont, P Giron, M Noeparast, H Vandenplas, P Aza-Blanc, ... Cell Death & Disease 13 (7), 611, 2022 | 3 | 2022 |
| Inhibition of PLK1 destabilizes EGFR and sensitizes EGFR-mutated lung cancer cells to small molecule inhibitor osimertinib C Eggermont, GJ Gutierrez, J De Grève, P Giron Cancers 15 (9), 2589, 2023 | 2 | 2023 |
| Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR? J De Greve, P Giron Translational Lung Cancer Research 9 (1), 1, 2020 | 2 | 2020 |
| Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes in Human Cancer F Vaeyens, JP Hetzel, M Mernberger, C Eggermont, C Olsen, K Maes, ... medRxiv, 2023.10. 21.23297089, 2023 | 1 | 2023 |
| ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework O Timofeev, P Giron, S Lawo, M Pichler, M Noeparast NPJ Precision Oncology 8 (1), 70, 2024 | | 2024 |
| Oocyte/zygote/embryo maturation arrest: a functional and clinical study expanding the phenotype of NOBOX variants A Van Der Kelen, S Uyttebroeck, SR Van de Voorde, I Segers, ... 24th annual meeting of the Belgian Society of Human Genetics (BeSHG), 2024 | | 2024 |
| High‐resolution and quantitative spatial analysis reveal intra‐ductal phenotypic and functional diversification in pancreatic cancer E Michiels, H Madhloum, S Van Lint, N Messaoudi, R Kunda, S Martens, ... The Journal of Pathology 262 (1), 76-89, 2024 | | 2024 |
